Literature DB >> 24442412

The significance of YKL-40 protein in liver fibrosis.

Hui Tao1, Jing-Jing Yang, Kai-Hu Shi, Cheng Huang, Lei Zhang, Xiong-Wen Lv, Jun Li.   

Abstract

OBJECTIVE: The aims of this review are to describe the present knowledge about YKL-40 protein, discuss its relation to liver fibrosis, and to look ahead at future perspectives of YKL-40 research.
INTRODUCTION: Liver fibrosis is characterized by excess collagen deposition, decreased extracellular matrix degradation and activation of hepatic stellate cells. Therefore, advancement in the identification of liver fibrosis biomarkers with diagnostic and prognostic values becomes an important tool for future molecular therapy. The molecular basis of YKL-40 in liver fibrosis is unknown.
METHODS: A PubMed database search was performed for studies of YKL-40 in liver injury and fibrosis. RESULTS AND
CONCLUSIONS: YKL-40 is an inflammatory glycoprotein involved in endothelial dysfunction by promoting chemotaxis, cell attachment and migration, reorganization, and tissue remodeling as a response to endothelial damage. Several studies demonstrate that elevated serum YKL-levels are independently associated with the presence of endothelial damage and even higher YKL-40 levels are documented in liver fibrosis. YKL-40 may play a key role in liver injury and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442412     DOI: 10.1007/s00011-013-0698-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  70 in total

1.  Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Authors:  Robert J Fontana; Jules L Dienstag; Herbert L Bonkovsky; Richard K Sterling; Deepa Naishadham; Zachary D Goodman; Anna S F Lok; Elizabeth C Wright; Grace L Su
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

2.  The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.

Authors:  Marina Harutyunyan; Michael Christiansen; Julia S Johansen; Lars Køber; Christian Torp-Petersen; Jens Kastrup
Journal:  Immunobiology       Date:  2011-11-18       Impact factor: 3.144

3.  Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

Authors:  Yukiko Saitou; Katsuya Shiraki; Yutaka Yamanaka; Yumi Yamaguchi; Tomoyuki Kawakita; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

4.  Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation.

Authors:  Veerle Bieghs; Sofie M A Walenbergh; Tim Hendrikx; Patrick J van Gorp; Fons Verheyen; Steven W Olde Damink; Ad A Masclee; Ger H Koek; Marten H Hofker; Christoph J Binder; Ronit Shiri-Sverdlov
Journal:  Liver Int       Date:  2013-04-25       Impact factor: 5.828

5.  YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation.

Authors:  Anne Roslind; Julia S Johansen
Journal:  Methods Mol Biol       Date:  2009

6.  Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C.

Authors:  Preeti Mehta; Robert Ploutz-Snyder; Jyotirmoy Nandi; Sekou R Rawlins; Schuyler O Sanderson; Robert A Levine
Journal:  Am J Gastroenterol       Date:  2008-03-25       Impact factor: 10.864

Review 7.  Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling.

Authors:  Mansi Prakash; Manish Bodas; Divya Prakash; Neelu Nawani; Madhukar Khetmalas; Abul Mandal; Cecilia Eriksson
Journal:  Cell Signal       Date:  2013-04-02       Impact factor: 4.315

8.  Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Authors:  Robert J Fontana; Herbert L Bonkovsky; Deepa Naishadham; Jules L Dienstag; Richard K Sterling; Anna S F Lok; Grace L Su
Journal:  Clin Gastroenterol Hepatol       Date:  2008-11-07       Impact factor: 11.382

9.  A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.

Authors:  Ning Ding; Ruth T Yu; Nanthakumar Subramaniam; Mara H Sherman; Caroline Wilson; Renuka Rao; Mathias Leblanc; Sally Coulter; Mingxiao He; Christopher Scott; Sue L Lau; Annette R Atkins; Grant D Barish; Jenny E Gunton; Christopher Liddle; Michael Downes; Ronald M Evans
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

10.  The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis.

Authors:  Erica Novo; Maurizio Parola
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
View more
  6 in total

Review 1.  Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation.

Authors:  Julia Kzhyshkowska; Alexandru Gudima; Kondaiah Moganti; Alexei Gratchev; Alexander Orekhov
Journal:  Transfus Med Hemother       Date:  2016-03-15       Impact factor: 3.747

2.  CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.

Authors:  Shaopeng Zhang; Xinzheng Dai; Yong Shi; Xiaowen Zhu; Yongjiu Dai; Xiaofeng Qian; Jian Gu
Journal:  Ann Transl Med       Date:  2021-04

3.  Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine.

Authors:  Driton Vela; Jovica Leshoski; Zana Vela; Muharrem Jakupaj; Mitko Mladenov; Ramadan B Sopi
Journal:  BMC Endocr Disord       Date:  2017-08-25       Impact factor: 2.763

4.  Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan.

Authors:  Wayne Shih-Wei Huang; Hung-Yu Lin; Chao-Bin Yeh; Li-You Chen; Ying-Erh Chou; Shun-Fa Yang; Yu-Fan Liu
Journal:  Int J Med Sci       Date:  2017-02-07       Impact factor: 3.738

5.  The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases.

Authors:  Zhenluo Jiang; Shuwei Wang; Jiancheng Jin; Sheng Ying; Zhigang Chen; Dedong Zhu; Bingxiu Xiao; Yaoren Hu; Yunsong Qian; Ting Cai; Liyun Fu
Journal:  J Clin Lab Anal       Date:  2020-01-08       Impact factor: 2.352

6.  Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Authors:  Obiageli Offor; Netanya Utay; David Reynoso; Anoma Somasunderam; Judith Currier; Jordan Lake
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.